Circulating microRNA-196a is an early gastric cancer biomarker

Tsung-Hsing Chen; Chieh Lee; Cheng-Tang Chiu; Yin-Yi Chu; Hao-Tsai Cheng; Jun-Te Hsu; Yung-Kuan Tsou; Ren-Chin Wu; Tse-Ching Chen; Nien-Chen Chang; Ta-Sen Yeh; Kwang-Huei Lin

doi:10.18632/oncotarget.23126

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Circulating microRNA-196a is an early gastric cancer biomarker

Tsung-Hsing Chen, Chieh Lee, Cheng-Tang Chiu, Yin-Yi Chu, Hao-Tsai Cheng, Jun-Te Hsu, Yung-Kuan Tsou, Ren-Chin Wu, Tse-Ching Chen, Nien-Chen Chang, Ta-Sen Yeh and Kwang-Huei Lin _

PDF | HTML | How to cite

Oncotarget. 2018; 9:10317-10323. https://doi.org/10.18632/oncotarget.23126

Metrics: PDF 1486 views | HTML 2044 views | ?

Abstract

Tsung-Hsing Chen1,2, Chieh Lee3, Cheng-Tang Chiu1, Yin-Yi Chu1, Hao-Tsai Cheng1, Jun-Te Hsu4, Yung-Kuan Tsou1, Ren-Chin Wu5, Tse-Ching Chen5, Nien-Chen Chang6, Ta-Sen Yeh4 and Kwang-Huei Lin6,7,8

1Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan

2Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan

3Department of Industrial Engineering and Management, Yuan Ze University College of Engineering, Chung-Li City, Taiwan

4Department of Surgery, Chang Gung Memorial Hospital, Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan

5Department of Pathology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan

6Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan

7Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan

8Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology Taoyuan, Taiwan

Correspondence to:

Kwang-Huei Lin, email: [email protected]

Ta-Sen Yeh, email: [email protected]

Keywords: microRNA-196a; precancerous gastric lesions; early gastric cancer; intestinal metaplasia; dysplasia

Received: April 11, 2017 Accepted: November 15, 2017 Published: December 07, 2017

ABSTRACT

MicroRNA-196a (miRNA-196a) is associated with the development of gastric cancer and metastasis. Intestinal metaplasia and low- or high-grade dysplasia are considered to be precursors of intestinal type gastric cancer. Accordingly, we investigated the expression of plasma miRNA-196a as an early detection biomarker in precancerous gastric lesions and early cancer (pT1a/b), which is otherwise treated with endoscopic submucosal dissection. Our data showed that levels of circulating (plasma) miRNA-196a were higher in patients with precancerous lesions/early gastric adenocarcinoma than in healthy controls. The area under the receiver operating characteristic curve (AUC) for healthy controls vs. intestinal metaplasia was 0.9736; healthy controls vs. low-grade/high-grade dysplasia 0.9495; and healthy controls vs. early gastric cancer 0.9318. These results indicate that circulating miRNA-196a is a novel biomarker for detection of early gastric cancer and its precursor.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23126

Publication Alerts

Research Papers:

Circulating microRNA-196a is an early gastric cancer biomarker

Abstract